PharmacoEconomics

, Volume 17, Issue 1, pp 37–52

Economic Evaluation of Specific Immunotherapy Versus Symptomatic Treatment of Allergic Rhinitis in Germany

Original Research Article

Abstract

Objective: To use published data to compare the economic consequences of specific immunotherapy (SIT) lasting 3 years with those of continuous symptomatic treatment in patients with either pollen or mite allergy.

Design and setting: The evaluation was conducted from the following 3 perspectives in Germany: (i) society; (ii) healthcare system; and (iii) statutory health insurance (SHI) provider. A modelling approach was used which was based on secondary analysis of existing data. The follow-up period was 10 years. The break-even point of cumulated costs, their difference per patient and the additional cost per additional patient free from asthma symptoms [incremental costeffectiveness ratio (ICER)] were used as target variables, each from the viewpoint of SIT. The types of costs were direct and indirect (society), direct (healthcare system) and those incurred by SHI (i.e. expenses). In the base-case analysis, the average values of the clinical parameters and average case-related costs/expenses were applied.

Main outcome measures and results: The break-even point was reached between year 6 and year 8 after the start of therapy, resulting in net savings of between 650 and 1190 deutschmarks (DM) per patient after 10 years. The ICERs of SIT were between -DM3640 and -DM7410, depending on study perspective and nature of the allergy (1990 values for symptomatic treatment and treatment of asthma, 1995 values for SIT; DM1 ≈ $US0.58). The sensitivity analysis demonstrated the robustness of the model and its results. First, all the independent variables of the model were varied. Secondly, the influence of the model variables was quantified using a deterministic model. SIT was more likely to result in net savings than in additional costs. An economic parameter (cost for symptomatic treatment) had the highest influence on the results.

Conclusions: This evaluation showed that SIT for 3 years is economically advantageous in patients who are allergic to pollen or mites and whose symptoms are inadequately controlled by continuous symptomatic treatment. After 10 years, the administration of SIT leads to net savings from the perspectives of society, the healthcare system and SHI (third-party payer) in Germany.

References

  1. 1.
    Kozma CM, Sadik MK, Watrous ML. Economic outcomes for the treatment of allergic rhinitis. Pharmacoeconomics 1996; 10: 4–13PubMedCrossRefGoogle Scholar
  2. 2.
    Sibbald B, Rink E. Epidemiology of seasonal and perennial rhinitis: clinical presentation and medical history. Thorax 1991; 46: 895–901PubMedCrossRefGoogle Scholar
  3. 3.
    Blaiss MS. How to determine the cost-effectiveness of available allergic rhinitis treatment. Drug Benefit Trends 1998; 10: 32–6Google Scholar
  4. 4.
    Magnussen H, Jorres R, Nowak D. Effect of air pollution on the prevalence of asthma and allergy: lessons from the German reunification. Thorax 1993; 48: 879–81PubMedCrossRefGoogle Scholar
  5. 5.
    Schmidt M, Martin E. Asthma und Antiasthmatika [asthma and antasthmatics]. Stuttgart: Wissenschaftliche Verlagsgesellschaft, 1994: 35Google Scholar
  6. 6.
    Weeke ER. Epidemiology of hay fever and perennial allergic rhinitis. Monogr Allergy 1987; 21: 1–20PubMedGoogle Scholar
  7. 7.
    Malling H-J, Weeke B. European Academy of Allergology and Clinical Immunology (EAACI) Position Paper: immunotherapy. Allergy 1993; 48 Suppl. 14: 9–35CrossRefGoogle Scholar
  8. 8.
    Sennekamp J, Kersten W, Hornung B. Empfehlungen zur Hyposensibilisierung mit Allergenextrakten: Ärzteverband Deutscher Allergologen e.V. (ÄDA) Allergo J 1995; 4: 205–12Google Scholar
  9. 9.
    Ring J. Angewandte Allergologie. München: MMV Medizin Verlag, 1995: 147Google Scholar
  10. 10.
    Bousquet J, Lockey RF, Malling H-J, editors. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO Position Paper. Allergy 1998; 53 Suppl. 44: 1–42Google Scholar
  11. 11.
    Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med 1995; 151: 969–74PubMedGoogle Scholar
  12. 12.
    Brecht JG, Jenke A, Köhler ME, et al. Empfehlungen der Deutschen Gesellschaft für Klinische Pharmakologie und Therapie zur Durchführung und Bewertung pharmakoökonomischer Studien. Med Klin 1995; 90: 541–6Google Scholar
  13. 13.
    Schreyer H. Ergebnisse einer Multicenterstudie zur Hyposensibilisierung von Pollinosis-Patienten mit einem tyrosinadsorbierten Gräser-und Roggenpollenextrakt (TA Tyrosin- Allergoid-Gräserpollen). Allergologie 1980; 2: 3–24Google Scholar
  14. 14.
    Von Mayenburg J, Düngemann H, Rakoski J, et al. Ergebnisse einer dreijährigen Hyposensibilisierung mit L-Tyrosin-Pollen-Allergoid. Allergologie 1981; 4: 36–42Google Scholar
  15. 15.
    Belmega C, Michel H. Klinische und serologische Beobachtungen bei der Depot-Hyposensibilisierung von Pollenallergikern. Allergologie 1982; 5: 283–9Google Scholar
  16. 16.
    Manger BJ, Hess B, Nüsslein HG, et al. Hyposensibilisierung von Pollinosis-Patienten mit Tyrosin-adsorbiertem Gräser- und Pollenallergoid. Klinische und immunologische Untersuchungen bei verschiedenen Behandlungsschematamit TATyrosin-Allergoid Gräserpollen. Allergologie 1984; 7: 222–8Google Scholar
  17. 17.
    Pegelow KO, Belin L, Broman P, et al. Immunotherapy with alginate-conjugated and alum-precipitated grass pollen extracts in patients with allergic rhinoconjunctivitis. Allergy 1984; 39: 275–90PubMedCrossRefGoogle Scholar
  18. 18.
    Nüsslein HG, Kleinlein M, Manger BJ, et al. Hyposensibilisierung von Pollinosis-Patienten mit Tyrosin-adsorbiertem Baumpollenallergoid: Klinische und immunologische Untersuchungen. Allergologie 1986; 9: 381–8Google Scholar
  19. 19.
    Frank E. Multicenterstudie zur Bewertung von Wirksamkeit und Verträglichkeit einer Hyposensibilisierungs-Behandlung mit Allergoid-Depot mit Kurzzeit-Dosierungschema (Allergovit Gräser-/Roggenpollen). Allergologie 1987; 10: 23–30Google Scholar
  20. 20.
    Felten G, Forck G, Herrmann E, et al. Hyposensibilisierung mit Tyrosin-adsorbiertem Baumpollenallergoid: Ergebnisse klinischer und immunologischer Untersuchungen. Allergologie 1988; 11: 68–81Google Scholar
  21. 21.
    Frank E. Frühzeitige Veränderung klinischer und immunologischer Parameter während der Hyposensibilisierung mit Depot-Allergoid. Extracta Derm 1989; 13: 104–5Google Scholar
  22. 22.
    Frank E, Agsten K, Narkus E. Untersuchungen zum Auftreten des sogenannten Etagenwechsels bei Pollinotikern und dem Einflu auf die Hyposensibilisierung [abstract]. Allergologie 1990; 13: 299Google Scholar
  23. 23.
    Ebner C, Kraft D, Ebner H. Booster immunotherapy (BIT). Allergy 1994; 49: 38–42PubMedCrossRefGoogle Scholar
  24. 24.
    Frank E, Joppich B, Distler A, et al. Kurz- und mittelfristige Erfolgskontrolle nach dreijähriger Hyposensibilisierung mit Gramineenpollen-Depot-Allergoid (Allergovit). Allergologie 1996; 19: 277–81Google Scholar
  25. 25.
    Mitsch A, Drachenberg KJ. Ergebnisse der spezifischen Immuntherapie (SIT) mit Tyrosin-adsorbierten Pollenallergoiden [abstract]. Allergologie 1996; 19: 522Google Scholar
  26. 26.
    Mitsch A, Drachenberg KJ. Ergebnisse der spezifischen Immuntherapie (SIT) mit TA Gräserpollen nach einem Jahr Behandlung [abstract]. Allergologie 1996; 19: 522Google Scholar
  27. 27.
    Wüthrich B, Günthard HP. Spätergebnisse der Hyposensibilisierungstherapie der Pollinosis. Schweiz Med Wschr 1974; 104: 713–7PubMedGoogle Scholar
  28. 28.
    Weeke ER. Epidemiology of hay fever and perennial allergic rhinitis. Monogr Allergy 1987; 21: 1–20PubMedGoogle Scholar
  29. 29.
    Rosendahl Lassen A, Jacobsen L, Svendsen UG. Trends in the use of specific immunotherapy. In: Ring J, Przybilla B, editors. New trends in allergy III. Berlin: Springer Verlag, 1991: 354–9CrossRefGoogle Scholar
  30. 30.
    Bronniman S, Burrows B. A prospective study of the natural history of asthma: remission and relapse rates. Chest 1986; 90: 480–4CrossRefGoogle Scholar
  31. 31.
    Markowe HLJ, Bulpitt CJ, Shipley MJ, et al. Prognosis in adult asthma: a national study. BMJ 1987; 295: 949–52PubMedCrossRefGoogle Scholar
  32. 32.
    Jackson R, Sears MR, Beaglehole R, et al. International trends in asthma mortality: 1970 to 1985. Chest 1988; 94: 914–9PubMedCrossRefGoogle Scholar
  33. 33.
    Wüthrich B, Häfner G. Pollinosis. II. Spezifische Hyposensibilisierung: Indikation und Behandlungsergebnisse. Schweiz med Wschr 1980; 110: 281–90PubMedGoogle Scholar
  34. 34.
    Renner B, Drachenberg KJ. Erste Ergebnisse einer Multicenter-Studie mit Tyrosin-adsorbierten Allergenextrakten (Tyrosin S) zur spezifischen Immuntherapie. Allergologie 1989; 12: 27–35Google Scholar
  35. 35.
    Norman PS, Lichtenstein LM, Kagey-Sobotka A, et al. Controlled evaluation of allergoid in the immunotherapy of ragweed hay fever. J Allergy Clin Immunol 1982; 70: 248–60PubMedCrossRefGoogle Scholar
  36. 36.
    Varney VA, Gaga M, Frew AJ, et al. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 1991; 302: 265–9PubMedCrossRefGoogle Scholar
  37. 37.
    Grammer LC, Shaughnessy MA, Suszko IM, et al. Persistence of efficacy after a brief course of polymerized ragweed allergen: a controlled study. J Allergy Clin Immunol 1984; 73: 484–9PubMedCrossRefGoogle Scholar
  38. 38.
    Brewczynski PZ, Kroon AM. A double blind, placebo-controlled study with the allergoid Purethal(R) [abstract]. Allergy 1992; 47 Suppl. 12: 90Google Scholar
  39. 39.
    Bousquet J, Becker WM, Hejjaoui A, et al. Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple-pollen species. J Allergy Clin Immunol 1991; 88: 43–53PubMedCrossRefGoogle Scholar
  40. 40.
    Østerballe O, Ipsen H, Weeke B, et al. Specific IgE response toward allergenic molecules during perennial hyposensitization: a three-year prospective double-blind study. J Allergy Clin Immunol 1983; 71: 40–6PubMedCrossRefGoogle Scholar
  41. 41.
    Warner JO, Price JF, Soothill JF, et al. Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma. Lancet 1978; II: 912–5CrossRefGoogle Scholar
  42. 42.
    Durham SR, Ying S, Varney VA, et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferongamma. J Allergy Clin Immunol 1996; 97: 1356–65PubMedCrossRefGoogle Scholar
  43. 43.
    Horst M, Hejjoui A, Horst V, et al. Double-blind, placebo-controlled rush immunotherapy with standardized Alternaria extract. J Allergy Clin Immunol 1990; 85: 460–72PubMedCrossRefGoogle Scholar
  44. 44.
    Dreborg S, Agrell B, Foucard T, et al. Adouble-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. Allergy 1986; 41: 131–40PubMedCrossRefGoogle Scholar
  45. 45.
    Cooper BS. Observations on the treatment of seasonal rhinitis with chemically modified pollen allergen. Br J Clin Pract 1976; 30: 217–21PubMedGoogle Scholar
  46. 46.
    Price JF, Warner JO, Hey EN, et al. A controlled trial of hyposensitization with absorbed tyrosine Dermatophagoides pteronyssinus antigen in childhood asthma: in vivo aspects. Clin Allergy 1984; 14: 209–19PubMedCrossRefGoogle Scholar
  47. 47.
    Walker SM, Randev P, Varney VA, et al. Grass pollen immunotherapy: a three year follow up study [abstract]. J Allergy Clin Immunol 1993; 94: 290Google Scholar
  48. 48.
    Uekötter J. Hyposensibilisierung von Asthmatikern im Kindesalter. Dt Derm 1990; 38: 335–41Google Scholar
  49. 49.
    Zimmermann T, Meyer-Ehmsen K. Diagnostik und Therapie der Sensibilisierung gegen Dermatophagoides pteronyssinus und Dermatophagoides farinae bei Kindern: Patientenbeobachtung über 3 Jahre. Allergologie 1988; 11: 503–8Google Scholar
  50. 50.
    Mosbech H, Østerballe O. Does the effect of immunotherapy last after termination of treatment? Allergy 1988; 43: 523–9PubMedCrossRefGoogle Scholar
  51. 51.
    Smith JM. Epidemiology and natural history of asthma, allergic rhinitis, and atopic dermatitis (eczema). In: Meddleton E, Reed CE, Ellis EF, editors. Allergy. Vol. II. Saint Louis (MO): CV Mosby, 1978: 633–58Google Scholar
  52. 52.
    Frank E. Retrospektive Untersuchung über die Hyposensibilisierungsbehandlung mit Novo-Helisen Depot. Allergologie 1994; 17: 154–9Google Scholar
  53. 53.
    Ring J. Spezifische Hyposensibilisierung: Wirkmechanismen, Erfolge und Probleme. Allergologie 1987; 10: 392–403Google Scholar
  54. 54.
    Pharma Daig + Lauer, editor. Grosse Deutsche Spezialitäten-Taxe, Lauer-Taxe mit Apotheken-Ein- und Verkaufspreisen. Fürth: 01. März 1997Google Scholar
  55. 55.
    Gesetz zur Entlastung der Beiträge in der Gesetzlichen Krankenversicherung 1996Google Scholar
  56. 56.
    Sozialgesetzbuch, Fünftes Buch, 1993 mit § 130 über den Rabatt in Höhe von fünf Prozent, den die gesetzlichen Krankenkassen von den Apotheken erhaltenGoogle Scholar
  57. 57.
    Kassenärztliche Bundesvereinigung, editor. Einheitlicher Bewertungsmaßstab (EBM). Köln: Deutscher Ärzte-Verlag, Stand 01. 1996Google Scholar
  58. 58.
    Büchner K. Die jährlichen Kosten der allergischen Rhinitis und des Asthmas in der Bundesrepublik Deutschland. Basel: Infratest-Suisse, 1993Google Scholar
  59. 59.
    Wettengel R, Volmer T. Asthma: Medizinische und ökonomische Bedeutung einer Volkskrankheit. Stuttgart: EuMe-Com, 1994Google Scholar
  60. 60.
    Brecht JG, Schädlich PK. Krankheitslast chronischer Krankheiten in Deutschland. Hamburg: InForMed GmbH, 1995Google Scholar
  61. 61.
    Drummond MF. Cost of illness studies: a major headache? Pharmacoeconomics 1992; 2: 1–4PubMedCrossRefGoogle Scholar
  62. 62.
    Davey PJ, Leeder SR. The cost of migraine: more than just a headache? Pharmacoeconomics 1992; 2: 5–7PubMedCrossRefGoogle Scholar
  63. 63.
    Coyle D, Tolley K. Discounting of health benefits in the pharmacoeconomic analysis of drug therapies: an issue for debate? Pharmacoeconomics 1992; 2: 153–62PubMedCrossRefGoogle Scholar
  64. 64.
    Bronstein IN, Semendjajew KA. Taschenbuch der Mathematik, 25., durchgesehene Auflage. Stuttgart: Teubner, 1991Google Scholar
  65. 65.
    Schädlich PK, Brecht JG. The cost effectiveness of acamprosate in the treatment of alcoholism in Germany: economic evaluation of the prevention of relapse with acamprosate in the management of alcoholism (PRAMA) study. Pharmacoeconomics 1998; 13: 719–30PubMedCrossRefGoogle Scholar
  66. 66.
    Glaeske G, von Stillfried D. Pharmakoökonomie als Entscheidungshilfe in der Arzneimittelversorgung: Perspektiven aus Sicht der GKV. Ersatzkasse 1995; 75: 298–307Google Scholar
  67. 67.
    Langley PC. The future of pharmacoeconomics: a commentary. Clin Ther 1997; 19: 762–9PubMedCrossRefGoogle Scholar
  68. 68.
    Toccaceli F, Rotigliano G, Bruno G, et al. Occurrence of asthma in patients with allergic rhinitis: prognostic value of clinical and laboratory tests. Respiration 1981; 42: 77–8CrossRefGoogle Scholar
  69. 69.
    Evans C. The use of consensus methods and expert panels in pharmacoeconomic studies: practical applications and methodological shortcomings. Pharmacoeconomics 1997; 12 (2 Pt 1): 121–9PubMedCrossRefGoogle Scholar
  70. 70.
    Launois R, Reboul-Marty J, Henry B, et al. A cost-utility analysis of second-line chemotherapy in metastatic breast cancer: docetaxel versus paclitaxel versus vinorelbine. Pharmacoeconomics 1996; 10: 504–21PubMedCrossRefGoogle Scholar
  71. 71.
    Norman, PS. Is there a role for immunotherapy in the treatment of asthma? Yes. Am J Respir Crit Care Med 1996; 154: 1225–6PubMedGoogle Scholar
  72. 72.
    Barnes PJ. Is there a role for immunotherapy in the treatment of asthma? No. Am J Respir Crit Care Med 1996; 154: 1227–8PubMedGoogle Scholar
  73. 73.
    Cook PR, Farias C. The safety of allergen immunotherapy: a literature review. Ear Nose Throat J 1998; 77: 378–88PubMedGoogle Scholar
  74. 74.
    Creticos PS, Reed CE, Norman PS, et al. Ragweed immunotherapy in adult asthma. N Eng J Med 1996; 334: 501–6CrossRefGoogle Scholar
  75. 75.
    Büchner K, Siepe M. Nutzen der Hyposensibilisierung unter wirtschaftlichen Aspekten. Allergo J 1995; 4: 156–63Google Scholar

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  1. 1.PAREXEL GmbH InForMed Outcomes Research & PharmacoeconomicsKlinikum WestendBerlinGermany

Personalised recommendations